Abstract
Oncolytic viruses have made a significant inroad in cancer drug development. Numerous clinical trials are currently investigating oncolytic viruses both as single agents or in combination with various immunomodulators. Oncolytic viruses (OV) are an integral pillar of immuno-oncology and hold potential for not only delivering durable anti-tumor responses but also converting “cold” tumors to “hot” tumors. In this review we will discuss one such promising oncolytic virus called Seneca Valley Virus (SVV-001) and its therapeutic implications. SVV development has seen seismic evolution over the past decade and now boasts of being the only OV with a practically applicable biomarker for viral tropism. We discuss relevant preclinical and clinical data involving SVV and how bio-selecting for TEM8/ANTXR1, a negative tumor prognosticator can lead to first of its kind biomarker driven oncolytic viral cancer therapy.
| Original language | English |
|---|---|
| Article number | 930207 |
| Journal | Frontiers in Molecular Biosciences |
| Volume | 9 |
| DOIs | |
| State | Published - Aug 26 2022 |
Bibliographical note
Publisher Copyright:Copyright © 2022 Corbett, Hallenbeck, Rychahou and Chauhan.
Keywords
- TEM8/ANTXR1
- drug development
- neuroendocrine carcinomas
- neuroendocrine tumors
- oncolytic virus
- seneca valley virus
- solid tumors
ASJC Scopus subject areas
- Biochemistry
- Molecular Biology
- Biochemistry, Genetics and Molecular Biology (miscellaneous)
